Drug intelligence / Profile preview

NEUK203-215

Development stage: Phase 1
Lead developer: Neukio Biotherapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

NEUK203-215 is an allogeneic, healthy donor-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting both CD19 and B-cell maturation antigen (BCMA). Developed by Neukio Biotherapeutics, it is designed to treat severe, refractory autoimmune diseases by depleting B cells and plasma cells, which are key drivers of autoantibody production. The dual-targeting approach (CD19 for B cells and BCMA for plasma cells) aims to provide a more comprehensive immune reset than single-target therapies. It is currently being evaluated in Phase 1 clinical trials for conditions including systemic lupus erythematosus, diffuse systemic sclerosis, inflammatory myopathy, and autoimmune bullous dermatosis.

Other names: NEUK203-215 InjectionNEUK-203-215 InjectionNEUK 203-215 Injection

Targets

CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on NEUK203-215.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEUK203-215.

Explore the full profile